The balance of biogenic amines as condition for normal behaviour

@article{Birkmayer2005TheBO,
  title={The balance of biogenic amines as condition for normal behaviour},
  author={Walther Birkmayer and Walter Danielczyk and E. Neumayer and Peter Franz Riederer},
  journal={Journal of Neural Transmission},
  year={2005},
  volume={33},
  pages={163-178}
}
An accumulation of norepinephrin, serotonin and dopamin exists in the brainstem. A decrease of biogenic amines in the brains of Parkinson's cases has been demonstrated. A substitution by the precursor L-DOPA produces an increase of dopamin in the brain and a decrease of serotonin. The high level of dopamin improves the akinesia and the depletion of serotonin causes a toxic delir. A substitution by l-tryptophan restores the balance and the Dopa-psychosis disappears. 
Die moderne medikamentöse Behandlung des Parkinsonismus
TLDR
The administration of L-DCPA effected an improvement in the akinesia for a short time only, and a combination of l-DOPA with a decarboxylase inhibitor (Ro4-4602) produced a more intensive effect over a longer period. Expand
L-Tryptophan: Biochemical, nutritional and pharmacological aspects
TLDR
The metabolism of tryptophan, its presence in the diet, the disorders associated with low tryPTophan levels due to low dietary intake, malabsorption, or high rates of metabolism, the therapeutic effects of tryptican and the side effects when it is used as a drug including eosinophilia myalgia syndrome are reviewed. Expand
Biochemical post-mortem findings in depressed patients
TLDR
Biochemical human post-mortem studies on depressed patients indicate an unspecific deficiency of neurotransmitters in several brain areas and a circadian disrhythm in depressed patients resulting in lowered VMA- and HVA-levels in urines during the morning and a remission to normal values in the evening. Expand
Nucleus ruber and L-Dopa psychosis: Biochemical post-mortem findings
TLDR
The values of L-tyrosine in all investigated areas were increased in parkinsonian patients as well as in L-Dopa psychosis, and 5-hydroxyindoleacetic acid levels show a similar pattern as 5-HT. Expand
Serotonergic mechanisms in Parkinson’s disease: opposing results from preclinical and clinical data
TLDR
The present review is aimed at bridging the gap between data from animal models of PD and data from human research, and will go into the importance of combining preclinical and clinical research data in order to gain more insight into the role of serotonin in PD. Expand
Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome
1. Significantly reduced values of noradrenaline in Parkinson's disease were observable in all brain areas which were studied. 2. A topographic distribution of free 3-methoxy-4-hydroxyphenylglycolExpand
EEG, 5-HTP-metabolism and acupuncture
TLDR
Since biochemical indications for an increased 5-HT turnover during acupuncture of several acupuncture-points are evident further investigations should be carried out to enable reliable correlations. Expand
Time course of nigrostriatal degeneration in parkinson's disease
TLDR
For the first time it could be demonstrated that the time course of nigrostriatal degeneration, independent of the age of the parkinsonian at the beginning of the illness, is linear for the last stage and the denervation progressively increases as the duration of illness progresses. Expand
Mood disorders in early Parkinson's disease
TLDR
There is an urgent need for more research into the putative additional antidepressant modes of action and efficacy of the various dopaminergic compounds that are used in that early stage of Parkinson's disease, in order to improve mood alterations. Expand
2 Diagnosis and Neuroprotection in Parkinson's Disease
TLDR
The current available diagnostic tools and concepts do not enable an early diagnosis of Parkinson’s disease, but they are necessary to perform an effective neuroprotective treatment regimes, since neuronal dopaminergic death is advanced at the clinical treshold of onset of motor symptoms. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 74 REFERENCES
L-Dopa: Effect on Concentrations of Dopamine, Norepinephrine, and Serotonin in Brains of Mice
Large doses of L-dopa given to mice produced marked increases in brain dopamine, no change in norepinephrine, and a remarkable decrease in brain serotonin. This reduction apparently results from aExpand
Aromatic amino acids and modification of parkinsonism.
TLDR
The interrelations between melanogenesis and extrapyramidal disease might be of fundamental importance and it was noted that chronic Parkinson's disease has a common precursor in the synthesis of both melanin and catecholamines. Expand
Psychiatric side effects of levodopa in man.
TLDR
The documentation and quantification of mental effects of levodopa is particularly important because of the potential for increasing basic understanding of the relationship between brain amines (particularly dopamine) and psychological states both normal and abnormal. Expand
L-Dopa-Induced Release of Cerebral Monoamines
TLDR
Observations support the hypothesis that a portion of exogenously administered L-dopa may enter central serotonin terminals and undergo decarboxylation to the amine with resultant displacement of the endogenous indoleamine from vesicular stores. Expand
Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems
SummaryThe distribution of noradrenaline und dopamine (3-hydroxytyramine) in human adult and newborn brains has been investigated. The greatest amounts of noradrenaline were found in theExpand
Tryptophan in the treatment of depression.
TLDR
The patients given tryptophan and a monoamine-oxidase inhibitor tended to show a greater improvement than those treated by tryPTophan alone, and the addition of potassium and carbohydrate may also enhance the antidepressive activity of tryptophile and a Monoamine-Oxidase inhibitors. Expand
Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.
TLDR
Preliminary experience suggests that α-methyl-dopa-hydrazine is a safe drug capable of inhibiting the peripheral decarboxylation of administered L- dopa, and subsequent reduction in the incidence of peripherally based side-effects may allow more rapid attainment of therapeutic levels, and a potentiation of the effects of L-Dopa on the central nervous system. Expand
Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral Decarboxylase
TLDR
The drug counteracts the increase of 5-hydroxytryptamine which is induced by 5- hydroxytryptophan less markedly in the brain than in extracerebral organs. Expand
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
  • A. Barbeau
  • Medicine
  • Canadian Medical Association journal
  • 1969
TLDR
The last 10 years have seen great activity in the investigation of cerebral catecholamines, particular attention having been paid to dopamine, but new approaches to the therapy have been tried and the sum total of these observations is to challenge peace of mind regarding a seemingly logical chain of events. Expand
Treatment of parkinsonism with levodopa.
TLDR
Under the most optimal circumstances, the best that can be expected from their judicious administration is a 20% reduction in the severity of symptoms with a modest improvement of functional capacity. Expand
...
1
2
3
4
5
...